Drug Therapy

  • An 86-year-old man with unexplained right-sided headache and vision loss
    Marc Ohlhausen, BS, Eden Bernstein, MD and Craig D. Nielsen, MD, FACP
    Cleveland Clinic Journal of Medicine September 2021, 88 (9) 494-501; DOI: https://doi.org/10.3949/ccjm.88a.20077

    Steroid treatment for suspected giant cell arteritis brought no improvement in vision or headache severity.

  • Autoimmune brain disease: Think before testing
    Brian F. Mandell, MD, PhD
    Cleveland Clinic Journal of Medicine August 2021, 88 (8) 420-421; DOI: https://doi.org/10.3949/ccjm.88b.08021

    Immune serologic tests are not specific for any defined clinical diagnosis and thus should not be used to drive therapeutic decisions.

  • Antiobesity drug therapy: An individualized and comprehensive approach
    Yael Mauer, MD, MPH, Marcie Parker, PharmD, BCACP and Sangeeta R. Kashyap, MD
    Cleveland Clinic Journal of Medicine August 2021, 88 (8) 440-448; DOI: https://doi.org/10.3949/ccjm.88a.20080

    As part of a comprehensive plan, these drugs can provide lasting obesity control and additional health benefits, including decreased cardiovascular risk.

  • The obesity paradox in heart failure: What is the role of cardiorespiratory fitness?
    Asad Khan, MD, Erik H. Van Iterson, PhD and Luke J. Laffin, MD
    Cleveland Clinic Journal of Medicine August 2021, 88 (8) 449-458; DOI: https://doi.org/10.3949/ccjm.88a.20098

    What should these patients be advised about weight management and about cardiorespiratory fitness, a major factor influencing the paradox?

  • ‘Guidelines to Practice’ series: Asthma in adults
    Brian F. Mandell, MD, PhD
    Cleveland Clinic Journal of Medicine July 2021, 88 (7) 365; DOI: https://doi.org/10.3949/ccjm.88b.07021

    A clinically useful summary, highlighting the practical and newer conceptual aspects of the guidelines.

  • Outpatient management of asthma in adults: A snapshot of the 2020 GINA report
    Kavya Kommaraju, MD and Mani Latifi, MD
    Cleveland Clinic Journal of Medicine July 2021, 88 (7) 377-380; DOI: https://doi.org/10.3949/ccjm.88a.20167

    A review of the guidelines, with a focus on what’s new and clinically important.

  • Statin intolerance and new lipid-lowering treatments
    Oltion Mesi, MD, Charlie Lin, MD, Haitham Ahmed, MD, MPH and Leslie S. Cho, MD
    Cleveland Clinic Journal of Medicine July 2021, 88 (7) 381-387; DOI: https://doi.org/10.3949/ccjm.88a.20165

    The benefits and safety of statin therapy are clear, but adverse effects continue to pose diagnostic and therapeutic challenges.

  • What antithrombotic therapy should I use for my patient with atrial fibrillation who underwent percutaneous coronary intervention or had an acute coronary syndrome?
    What antithrombotic therapy should I use for my patient with atrial fibrillation who underwent percutaneous coronary intervention or had an acute coronary syndrome?
    Andrew S. Tseng, MD, MPH, Fadi E. Shamoun, MD, Lisa A. Marks, MLS and Neera Agrwal, MD, PhD
    Cleveland Clinic Journal of Medicine July 2021, 88 (7) 389-392; DOI: https://doi.org/10.3949/ccjm.88a.19081

    The risk of thrombosis should be balanced with the risk of bleeding.

  • The current state of tobacco cessation treatment
    Humberto K. Choi, MD, FCCP, Jorge Ataucuri-Vargas, MD, Charlie Lin, MD and Amanda Singrey, PharmD, BCACP, CTTS
    Cleveland Clinic Journal of Medicine July 2021, 88 (7) 393-404; DOI: https://doi.org/10.3949/ccjm.88a.20099

    Behavioral interventions and pharmacotherapy increase success rates. Alternative treatments should not replace or delay the use of known effective therapies.

  • Promoting physical activity in older women to maximize health
    Augustine Chavez, MD, Robert Scales, PhD and Juliana M. Kling, MD, MPH
    Cleveland Clinic Journal of Medicine July 2021, 88 (7) 405-415; DOI: https://doi.org/10.3949/ccjm.88a.20170

    The optimal type, intensity, and level required to achieve specific health outcomes depend on the disease the patient and clinician are trying to prevent or manage.

Pages